Results 41 to 50 of about 35,440 (172)

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence

Therapeutic Advances in Urology, 2017
Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by
Mimma Rizzo, Camillo Porta
doaj   +1 more source

The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA.

PLoS ONE, 2012
Constitutive activation of pro-survival kinases has become a promising target of small molecules with an increasing interest in developing multi-targeted agents.
Jing Sun, Quanhong Sun, Matthew F Brown, Crissy Dudgeon, Julie Chandler, Xiang Xu, Yongqian Shu, Lin Zhang, Jian Yu   +8 more
doaj   +1 more source

Dual-Functional Polymeric Micelles Co-Loaded with Antineoplastic Drugs and Tyrosine Kinase Inhibitor for Combination Therapy in Colorectal Cancer

Pharmaceutics, 2022
The aim of this research was to evaluate the receptor tyrosine kinase inhibitor Sunitinib combined with SN-38 in polymeric micelles for antitumor efficacy in colorectal cancer.
Ying-Hsia Shih, Cheng-Liang Peng, Ping-Fang Chiang, Ming-Jium Shieh   +3 more
doaj   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Mitochondria‐endoplasmic reticulum organelle glue as maturation promoter for origination/dimensional dual‐cross cardiomyocytes

BMEMat, EarlyView.
Mitochondria‐endoplasmic reticulum contact sites (MERCS) are areas where the mitochondria and endoplasmic reticulum closely interact. In this study, we utilize synthetic organelle glues to artificially engineer MERCS for regulating cardiomyocyte development, through which the immature and chemo‐plasticity issues of undifferentiated cells are addressed.
Wei Tang, Hao Sun, Chenqi Duan, Jiajia Chang, Yuxing Wang, Ming Zhao, Huiyue Zhao, Shan Lu, Yang Yang, Da Huo   +9 more
wiley   +1 more source

Inhibition of Autophagy Enhances Sunitinib-Induced Cytotoxicity in Rat Pheochromocytoma PC12 cells

Journal of Pharmacological Sciences, 2013
Sunitinib is an oral multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity that mainly targets vascular endothelial growth factor receptors, and recently, it has been shown to be an active agent for the treatment of ...
Tatsuhiko Ikeda, Kiyo-aki Ishii, Yuria Saito, Masahiro Miura, Aoi Otagiri, Yasushi Kawakami, Hitoshi Shimano, Hisato Hara, Kazuhiro Takekoshi   +8 more
doaj   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC

Neoplasia: An International Journal for Oncology Research, 2015
Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase in progression-free survival for patients with metastatic RCC (mRCC), but mRCC remains largely incurable.
Jeannette C. Oosterwijk-Wakka, Mirjam C.A. de Weijert, Gerben M. Franssen, William P.J. Leenders, Jeroen A.W.M. van der Laak, Otto C. Boerman, Peter F.A. Mulders, Egbert Oosterwijk   +7 more
doaj   +1 more source

Time‐Dependent Bias and Prognostic Confounding in Exposure–Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure–response (E–R) analyses of sunitinib in metastatic renal cell carcinoma (mRCC) have supported concentration‐guided dose escalation. However, such analyses may be biased when exposure metrics incorporate post‐baseline dose modifications, time‐varying apparent clearance, or baseline factors that influence both pharmacokinetics and clinical ...
Han Liu, Lena E. Friberg
wiley   +1 more source

circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway

Cell Death and Disease, 2023
Renal cell carcinoma (RCC) is characterized by the difficulties in early diagnosis and the propensity to metastases. For advanced RCC, sunitinib targeted therapy is the clinically recommended first-line drug and the major challenge of sunitinib treatment
Yi Shou, Changjie Yue, Qi Wang, Jingchong Liu, Jiaju Xu, Qi Miao, Di Liu, Hongmei Yang, Yuenan Liu, Xiaoping Zhang   +9 more
doaj   +1 more source